MedTrace Logo

Famotidine in Schizophrenia

NCT01946295 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2015-04-14

No results posted yet for this study

Summary

Objective of the trial is to study if famotidine add-on treatment is more effective than placebo add-on in reducing symptoms of schizophrenia among patients receiving insufficient response to ongoing antipsychotic treatment.

Conditions

Interventions

DRUG

Famotidine

100mg x 2 p.o.

DRUG

Placebo

Sponsors & Collaborators

  • Karolinska Institutet

    collaborator OTHER

  • Region Stockholm

    collaborator OTHER_GOV

  • City of Helsinki

    collaborator OTHER

  • Stanley Medical Research Institute

    collaborator OTHER

  • Ahokas foundation, Finland

    collaborator UNKNOWN

  • Jesper Ekelund

    lead OTHER

Principal Investigators

  • Jesper Ekelund, MD, PhD · University of Helsinki

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Finland
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01946295 on ClinicalTrials.gov